Regorafenib

From Ganfyd

Jump to: navigation, search

Contents

Introduction

A non-specific multikinase inhibitor with activity against:

Because of its resulting potential toxicity it may be most useful after escape from more directed agents in chemotherapeutic regimes[1].

Clinical Use

In development in a wide range of tumours including GIST, lung cancer, hepatocellular carcinoma and renal cell carcinoma[2].

Indications

Administration

Oral, depending upon protocol but typically 160mg daily during a cycle

Clinical Issues

Fatal hepatic toxicity reported

Contra-indications

Cautions and Interactions

Side effects

  • Malaise
  • Anorexia
  • Diarrhoea
  • Hypertension
  • Rash
  • Hand-foot syndrome (palmar-plantar erythrodysesthesia)
  • Mucositis

Special advice

Pharmacology

A bi-aryl urea compound

References

Personal tools